The decision follows the company’s progress with its lead drug candidate, IkT-001Pro, which aims to treat pulmonary arterial hypertension (PAH). Inhibikase Therapeutics received IND-clearance ...

ACR: Albumin:creatinine ratio; CVD: Cardiovascular disease; eGFR: Estimated glomerular filtration rate (measured in mls/min/1.73 m 2 of body surface area); HDL-C: HDL cholesterol; LDL-C: LDL ...

Fenofibrate and its active metabolite, fenofibric acid, are primarily excreted by the kidneys. It is nondialysable, and studies in patients with moderate chronic kidney disease (GFR <50 ml/min/1. ...

In 2024, it secured a $30 million milestone payment from Gilead for IND clearance and continues to ... diseases that cause high blood pressure (PAH and PH-ILD). Unlike other treatments that ...

These gains highlight the corporation’s strong market position in treating pulmonary arterial hypertension (PAH) and other ...

In 26 instances the PAH clearance and the PAH-extraction ratio were determined simultaneously. The dye-PAH flow ratio averaged 0.98 for the whole series. The limitations of the dye method have been ...

Verve Therapeutics announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for VERVE-102 for the treatment of patients living with ...

The decision follows the company’s progress with its lead drug candidate, IkT-001Pro, which aims to treat pulmonary arterial hypertension (PAH). Inhibikase Therapeutics received IND-clearance from the ...

PAH therapies improved hemodynamic parameters and reduced NT-proBNP levels in PH-ILD patients, indicating potential benefits. Precision medicine could help identify PH-ILD patients who may benefit ...

The CESTAT also held that the burden is on the Department to establish the classification of goods as HSD, which conforms to ...

Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in ...